The ERN PaedCan project is currently focusing on two key aspects of its strategy including:
Expansion of the ESCP project to include second-line treatment recommendations.
ERN PaedCan is expanding the ESCP project to include recommendations for second-line treatment. Based on feedback from several European Clinical Trial Group chairs and discussions with the ERN PaedCan Oversight Committee, we have concluded that the ESCP documents should include a chapter on second-line treatment options, where appropriate.
We understand that due to the complexity of relapse treatments, it may not be possible to develop such chapters for all cancer types. Nonetheless, we aim to provide recommendations for first relapses and propose including an algorithm for various relapse scenarios as a central feature.
Development of ORPHAcodes
In collaboration with SIOPE and Orphanet, ERN PaedCan is working to develop harmonised ORPHAcodes for paediatric cancer, to facilitate interoperability of current coding systems.
Experts will be involved in revising the nomenclature and classification alongside the Orphanet nomenclature managers, contributing their scientific and clinical knowledge. This collaboration ensures that the actions discussed, validated, and implemented in the Orphanet database, result in an accurate representation of the current knowledge on rare diseases and meet the needs of the paediatric oncology community.
In early October 2024, ERN PaedCan invited ESCPs authors to participate as experts in the development of ORPHAcodes. The reviewed and validated classification is expected to be completed by the end of 2025.
For more information about ERN PaedCan, please visit our website Home - ERN PaedCan or contact us at ernpaedcan@ccri.at
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.